Company Overview
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.27.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +41.03% |
| 6 Months: | -24.23% |
| 3 Months: | +14.57% |
| 1 Month: | -2.81% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)50.09 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 55.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CING Cingulate Inc. PHARMA | 5.19 | -1.46 | $75.47M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 3.71M | 4.65M | 6.00M | 5.59M | 7.92M |
| Operating Income | -1.33M | -1.42M | -15.28M | -5.01M | -4.05M | -3.97M | -3.85M | -6.36M | -5.75M | -2.95M | -3.21M | -3.28M | -3.71M | -4.65M | -6.00M | -5.59M | -7.92M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | -3.54M | -4.50M | -5.89M | -5.46M | -7.80M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | -3.85M | -4.79M | -7.34M | -6.27M | -9.31M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | -1.33M | -1.43M | -15.29M | -5.00M | -4.04M | -4.03M | -4.00M | -6.62M | -5.98M | -2.97M | -3.23M | -4.13M | -3.85M | -4.79M | -7.34M | -6.27M | -9.31M |
| Diluted EPS | - | - | - | - | -0.36 | -0.36 | -7.08 | -6.79 | -72.60 | -7.21 | -5.47 | -2.34 | -1.04 | -0.98 | -1.23 | -0.87 | -0.95 |
| R&D Expense | 562.52K | 793.59K | 5.79M | 2.76M | 2.18M | 2.12M | 2.13M | 4.46M | 3.92M | 1.81M | 1.88M | 1.43M | 2.22M | 2.70M | 2.85M | - | 2.18M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -7.08M | -20.68M | -17.50M | -22.76M | -15.64M | -19.94M |
| Net Income | -7.18M | -20.71M | -17.68M | -23.53M | -16.56M | -22.45M |
| Diluted EPS | - | - | -29.35 | -311.99 | -10.86 | -4.44 |
| R&D Expense | 5.09M | 8.41M | 9.00M | 15.49M | 9.45M | 9.77M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 5.79M | - | 11.41M | 3.49M | 14.86M | 15.07M |
| Current Assets | - | - | - | 7.87M | 578.59K | 12.66M | 12.01M |
| Cash & Equivalents | - | 1.20M | - | 5.36M | 52.42K | 12.21M | 10.95M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | 234.43K | 14.62K | 26.32K | 8.01K |
| Total Liabilities | - | 4.50M | - | 7.52M | 10.36M | 7.41M | 12.56M |
| Current Liabilities | - | 3.36M | - | 7.01M | 10.23M | 4.97M | 10.31M |
| Long Term Debt | - | - | - | - | - | 2.44M | 1.15M |
| Total Debt | - | - | - | 5.87M | 3.51M | 5.10M | 8.79M |
| Total Equity | 615.88K | 1.29M | - | 3.88M | -6.87M | 7.46M | 2.51M |
| Shares Outstanding | - | - | - | 47.12K | 97.29K | 3.40M | 7.25M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -6.81M | - | -15.88M | -15.03M | -18.45M | -17.25M |
| Investing Cash Flow | -384.17K | - | -152.65K | -224.10K | -211.80K | -162.14K |
| Financing Cash Flow | 7.97M | - | 4.90M | 9.95M | 30.82M | 16.15M |
| Capital Expenditure | -402.10K | - | -153.42K | -224.10K | -211.80K | -162.14K |
| Free Cash Flow | -7.21M | - | -16.04M | -15.26M | -18.66M | -17.41M |
| Net Change in Cash | - | - | -11.14M | -5.30M | 12.16M | -1.26M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | -555.8% | - | -455.3% | 342.6% | -222.1% | -894.8% |
| ROCE % | -292.0% | - | -398.5% | 338.0% | -158.2% | -418.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 3.93% | 570.87K | $2.99M |
| 2 | Chicago Partners Investment Group LLC | 1.30% | 188.43K | $987.37K |
| 3 | Raymond James Financial, Inc. | 1.15% | 166.90K | $874.54K |
| 4 | Kestra Advisory Services, LLC | 1.04% | 151.50K | $793.86K |
| 5 | Geode Capital Management, LLC | 0.99% | 144.64K | $757.89K |
| 6 | Renaissance Technologies, LLC | 0.88% | 127.50K | $668.10K |
| 7 | Vanguard Fiduciary Trust Co | 0.54% | 79.16K | $414.80K |
| 8 | Blackrock Inc. | 0.37% | 53.13K | $278.40K |
| 9 | Bcv Asset Management Inc. | 0.35% | 51.20K | $268.29K |
| 10 | State Street Corporation | 0.33% | 47.89K | $250.93K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CING
Cingulate Stock Price Forecast. Should You Buy CING? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE9KYlFFaXNvdHVuTDcyNjdqZnlCM0xkNEk0aXV4aW1sNEFRUHRUMzRZWGVUYkNMOW9XZnc3eTlrcEN2WWxGS2NvSw?oc=5" target="_blank">Cingulate Stock Price Forecast. Should You Buy CING?</a> <…
Precision Trading with CING Corporation (CING) Risk Zones - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxPRXBvMTJVc2xvSlZ1d01ybmtvd0xIeVNqc21wNGpGNkVVd0tfMXNfeEF1WEtia2p4VUVrdlRaM045TUx6YWVESXp0TGFXVHRfekliR1MwamJPR0l2eFVMNUdHOWk2aF83YWtSVUdiQVBHUzFtSGdFdE5jMXc5YmhnNW9WTkp0ZlRYVmxaMW…
Here is Why Cingulate (CING) is One of the Best NASDAQ Growth Stocks to Buy and Hold Forever - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxQYzJRSlRLWWpNYXY3SnZ0anJWTEd1RHZCZXV4X2dQaVFqZzl3a0RqSVl6OW15dUZjVUxrUEk1QWlhWE1heFFmUS1oV0lRcXdHeW81aEFpUC1IRUVELXhIVEx3Q2FKNmxSU3Y1M21ib0FCalBjSVBwVURJNHdwSkw2N3JLNlN2d0RjbWFZQl…
$CING stock is down 10% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNVndORXR0bG9uekc4OGRoU1NLUU56NU1maXZnenVNeEhVcU9IMTVWNmU2UFloMmFOS0JIcWxPR3RoXzhGLW5sb0JZeTJwbkIybDNVLXdGSlFsV091azZ0ZGMwYkVEVkhqY0FaM3RiWC1Oemk3ZlB5WGVab0FiRFRWLUxZVWVQUVJLSnZLWX…
CING - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBPeTB3Y0dvTHYwN3ZmTlpjNkk2S043Vk1Xc1cxYlhRXzNOeXdMNmRzQllTc3ptakVrSFFWOXBHOHpnc2hCYVE?oc=5" target="_blank">CING</a> <font color="#6f6f6f">Finviz</font>…
Cingulate's ADHD candidate improved scores at all three doses - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxQVENndkxVaXRzY0VBX1V0WkhZX3d0RUktRnBZTHdkTGhheVA3Mm9jeWZwSmZ4ZHR3cmZCYTFwOEhZenJrSktIdzdQcDNlc3V5T1VBQmxnUHBSV3h4YmtxRndPRXpYRDA1NzhZcHRoMmJ0Qzh0SkIzQ0JoUEJ6SFoweDd3dWNibm0wSnNobF…
CING — Frequently Asked Questions
What is the current share price of Cingulate Inc. (CING)?
As of 2026-09-19 21:16 PDT, Cingulate Inc. (CING) trades at $5.19 on NasdaqCM. Its 52-week range is $3.33 to $11.66.
What is the market capitalisation of CING?
Cingulate Inc. (CING) has a market capitalisation of $75.47M on NasdaqCM.
What is the P/E ratio of CING?
CING trades at a trailing price-to-earnings (P/E) ratio of -1.46. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.08.
Is CING a good stock to buy?
This page provides a data-driven analysis of Cingulate Inc. (CING), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.